

Bortezomib-melphalan-prednisone *versus* lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial

Authors

Sara Bringhen,¹ Lorenzo Cani,² Nicola Giuliani,³ Silvia Mangiacavalli,⁴ Giulia Benevolo,¹ Elisabetta Antonioli,⁵ Renato Zambello,⁶ Roberto Ria,⁷ Iolanda Donatella Vincelli,⁸ Sonia Ronconi,⁹ Sonia Morè,¹⁰ Antonietta Pia Falcone,¹¹ Alessandro Allegra,¹² Mattia D'Agostino,² Andrea Evangelista,¹³ Andrea Capra,¹⁴ Elisa Sciorsci,¹⁵ Paola Curci,¹⁶ Patrizia Tosi,¹⁷ Anna Marina Liberati,¹⁸ Anna Maria Cafro,¹⁹ Angelo Belotti,²⁰ Francesca Patriarca,²¹ Donato Mannina,²² Katia Mancuso,^{23,24} Francesco Cattel,¹⁵ Giovannino Ciccone,¹³ Benedetto Bruno,² Mario Boccadoro^{14,25} and Alessandra Larocca²

¹SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Department of Oncology, AOU Città della Salute e della Scienza di Torino, University of Torino, Torino; ²Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino; ³University of Parma & AOU Parma, Parma; ⁴Division of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia; ⁵Hematology Unit, AOU Careggi, Florence; ⁶Department of Medicine (DIMED), Hematology, Padua University, Padua; ⁷University of Bari Aldo Moro Medical School, Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), Bari; ⁸Divisione di Ematologia, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria; ⁹IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola; ¹⁰AOU delle Marche, Università Politecnica delle Marche, Ancona; ¹¹Hematology, IRCCS "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo; ¹²Division of Hematology, Department of Human

Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, Messina; ¹³Unit of Clinical Epidemiology, AOU Città della Salute e della Scienza di Torino and CPO Piemonte, Torino; ¹⁴European Myeloma Network (EMN); ¹⁵SC Farmacia Ospedaliera, AOU Città della Salute e della Scienza di Torino, Torino; ¹⁶Hematology and Stem Cell Transplantation Unit, AOU Consorziale Policlinico, Bari; ¹⁷UO Ematologia, Ospedale di Rimini, Rimini; ¹⁸A.O. Santa Maria di Terni – Università degli Studi di Perugia, Terni–Perugia; ¹⁹SC Ematologia, GOM Niguarda, Milano; ²⁰Department of Hematology, ASST Spedali Civili di Brescia, Brescia; ²¹Hematologic Clinic and Transplant Center, University Hospital of Central Friuli, DMED, University of Udine, Udine; ²²Oncology-Hematology Department, Papardo Hospital, Messina; ²³IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna; ²⁴Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna and ²⁵Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy

Correspondence:

S. BRINGHEN - sarabringhen@yahoo.com

<https://doi.org/10.3324/haematol.2025.287510>

Received: February 11, 2025.

Accepted: July 22, 2025.

Early view: July 31, 2025.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license 

Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial

Appendix

Summary

Supplementary tables.....2

 Table S1. Treatment-emergent adverse events in the safety population2

Supplementary figures.....4

 Figure S1. Trial profile4

 Figure S2. Progression-free survival on the subsequent line of therapy (PFS2) and time to next treatment (TNT) in the intention-to-treat population.....5

a) PFS25

b) TNT.....5

Supplementary tables

Table S1. Treatment-emergent adverse events in the safety population


	VMP arm (n=107)		Rd arm (n=112)	
	Grade 3-4	Grade 5	Grade 3-4	Grade 5
Hematologic, n (%)	27 (25)	-	31 (28)	-
Anemia	6 (6)	-	7 (6)	-
Thrombocytopenia	16 (15)	-	-	-
Neutropenia	20 (19)	-	28 (25)	-
Other	3 (3)	-	3 (3)	-
Non-hematologic, n (%)	38 (34)	1 (1)	25 (23)	2 (2)
Cardiac	2 (2)	-	3 (3)	-
Arrhythmia	-	-	2 (2)	-
Cardiac failure	1 (1)	-	1 (1)	-
Cardiac arrest	-	-	-	-
Other	1 (1)	-	-	-
Gastrointestinal	5 (5)	-	4 (4)	-
Constipation	4 (4)	-	1 (1)	-
Diarrhea	-	-	3 (3)	-
Nausea	1 (1)	-	-	-
Fatigue	1 (1)	-	3 (3)	-
Worsening of general conditions		-	-	1 (1)
Infections	4 (4)	-	10 (9)	-
Pneumonia	1 (1)	-	4 (4)	-
Bronchitis	1 (1)	-	4 (4)	-
COVID-19 pneumonia	2 (2)	1 (1)	2 (2)	-
Sepsis	1 (1)	-	1 (1)	-
Urinary tract infection	1 (1)	-	1 (1)	-
Other	-	-	2 (2)	-
Second primary malignancies	-	-	1 (1)	1 (1)

Renal and urinary disorders	5 (5)	-	5 (4)	-
Acute kidney injury	4 (4)	-	3 (3)	-
Chronic kidney disease	-	-	2 (2)	-
Other	2 (2)	-	-	-
Nervous system disorders	10 (9)	-	4 (4)	-
Stroke	-	-	1 (1)	-
Neuropathy	6 (6)	-	1 (1)	-
Other	3 (3)	-	3 (3)	-
Respiratory disorders	2 (2)	-	1 (1)	-
Dyspnea	1 (1)	-	1 (1)	-
Respiratory failure	1 (1)	-		-
Skin disorders	1 (1)	-	12 (11)	-
Rash	1 (1)	-	12 (11)	-
Other	-	-	1 (1)	-
Thromboembolism	1 (1)	-	2 (2)	-
DVT	1 (1)	-	-	-
Pulmonary embolism	-	-	2 (2)	-

Abbreviations. VMP, bortezomib-melphalan-prednisone; Rd, lenalidomide-dexamethasone; DVT, deep vein thrombosis.

Supplementary figures


Figure S1. Trial profile




Abbreviations. IQR, interquartile range; VMP, bortezomib-melphalan-prednisone; Rd, lenalidomide-dexamethasone; AEs, adverse events

Figure S2. Progression-free survival on the subsequent line of therapy (PFS2) and time to next treatment (TNT) in the intention-to-treat population

a) PFS2



b) TNT



Abbreviations. PFS2, progression-free survival on the subsequent line of therapy; TNT, time to next treatment; VMP, bortezomib-melphalan-prednisone; Rd, lenalidomide-dexamethasone.